Medicinal cannabis provider Creso Pharma (ASX:CPH)
CEO, Dr Miri Halperin Wernli discusses its hemp extract licencing agreement with Domaco, Dr. med. Aufdermaur AG.
The agreement with Domaco is for the development, the manufacture and commercialisation of two new second generation cannabinoid nutraceutical products for use in human health.
Domaco is a traditional Swiss, high tech food and pharma company in business since 1922. It is a leading European producer of innovative products both for global pharmaceutical and global food companies.
The agreement also includes the development of new animal health nutraceutical products for companion animals, with a novel delivery technology.
Creso Pharma will retain all of the IP rights for all of the developed products.